Clinicopathologic features associated with efficacy and long-term survival in metastatic melanoma patients treated with BRAF or combined BRAF and MEK inhibitors

Cancer

Volumn 121, Issue 21, 2015, Pages 3826-3835

  Menzies, Alexander M ^a,b,c   Wilmott, James S ^a,b   Drummond, Martin ^a,b   Lo, Serigne ^a,b   Lyle, Megan ^a,b   Chan, Matthew M K ^d   Thompson, John F ^a,b,e,f   Guminski, Alex ^a,b,c   Carlino, Matteo S ^a,b,d   Scolyer, Richard A ^a,b,e   Kefford, Richard F ^a,b,d,g   Long, Georgina V ^a,b  

^a MELANOMA INSTITUTE AUSTRALIA   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

^c ROYAL NORTH SHORE HOSPITAL   (Australia)

^d WESTMEAD HOSPITAL   (Australia)

^e ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^f Mater Hospital   (Australia)

^g MACQUARIE UNIVERSITY   (Australia)

Author keywords

biomarker; BRAF; inhibitor; lactate dehydrogenase (LDH); melanoma; survival

Indexed keywords

B RAF KINASE; B RAF KINASE INHIBITOR; BINIMETINIB; DABRAFENIB; ENCORAFENIB; IPILIMUMAB; LACTATE DEHYDROGENASE; LENVATINIB; MITOGEN ACTIVATED PROTEIN KINASE KINASE INHIBITOR; PEMBROLIZUMAB; TRAMETINIB; VEMURAFENIB; ANTINEOPLASTIC AGENT; IMIDAZOLE DERIVATIVE; INDOLE DERIVATIVE; MITOGEN ACTIVATED PROTEIN KINASE KINASE KINASE; OXIME; PROTEIN KINASE INHIBITOR; PYRIDONE DERIVATIVE; PYRIMIDINONE DERIVATIVE; SULFONAMIDE; TUMOR MARKER;

ADULT; ARTICLE; BRAIN METASTASIS; CANCER SURVIVAL; CLINICAL FEATURE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; FEMALE; GENDER; GENOTYPE; HUMAN; LACTATE DEHYDROGENASE BLOOD LEVEL; LONG TERM SURVIVAL; MAJOR CLINICAL STUDY; MALE; METASTATIC MELANOMA; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; SURVIVAL PREDICTION; SURVIVAL TIME; TREATMENT RESPONSE; TREATMENT WITHDRAWAL; ADOLESCENT; AGED; ANTAGONISTS AND INHIBITORS; BLOOD; COMPARATIVE STUDY; DRUG COMBINATION; FOLLOW UP; GENETICS; MELANOMA; MIDDLE AGED; PATHOPHYSIOLOGY; SECONDARY; SEX DIFFERENCE; SKIN NEOPLASMS; SURVIVAL RATE; TREATMENT OUTCOME; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; BIOMARKERS, TUMOR; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; GENOTYPE; HUMANS; IMIDAZOLES; INDOLES; L-LACTATE DEHYDROGENASE; MALE; MAP KINASE KINASE KINASES; MELANOMA; MIDDLE AGED; OXIMES; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS B-RAF; PYRIDONES; PYRIMIDINONES; SEX FACTORS; SKIN NEOPLASMS; SULFONAMIDES; SURVIVAL RATE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84945487247     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.29586     Document Type: Article

References (37)

1. Chapman PB, Hauschild A, Robert C, et al., Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011; 364: 2507-2516.
2. Hauschild A, Grob JJ, Demidov LV, et al., Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet. 2012; 380: 358-365.
3. Long GV, Stroyakovskiy D, Gogas H, et al., Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma. N Engl J Med. 2014; 371: 1877-1888.
4. Robert C, Karaszewska B, Schachter J, et al., Improved overall survival in melanoma with combined dabrafenib and trametinib. N Engl J Med. 2015; 372: 30-39.
5. Larkin J, Ascierto PA, Dreno B, et al., Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. N Engl J Med. 2014; 371: 1867-1876.
6. Balch CM, Gershenwald JE, Soong SJ, et al., Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol. 2009; 27: 6199-6206.
7. Manola J, Atkins M, Ibrahim J, Kirkwood J,. Prognostic factors in metastatic melanoma: a pooled analysis of Eastern Cooperative Oncology Group trials. J Clin Oncol. 2000; 18: 3782-3793.
8. Davies MA, Liu P, McIntyre S, et al., Prognostic factors for survival in melanoma patients with brain metastases. Cancer. 2011; 117: 1687-1696.
9. Fife KM, Colman MH, Stevens GN, et al., Determinants of outcome in melanoma patients with cerebral metastases. J Clin Oncol. 2004; 22: 1293-1300.
10. Joosse A, Collette S, Suciu S, et al., Superior outcome of women with stage I/II cutaneous melanoma: pooled analysis of four European Organisation for Research and Treatment of Cancer phase III trials. J Clin Oncol. 2012; 30: 2240-2247.
11. Falchook GS, Long GV, Kurzrock R, et al., Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial. Lancet. 2012; 379: 1893-1901.
12. Ascierto PA, Minor D, Ribas A, et al., Phase II trial (BREAK-2) of the BRAF inhibitor dabrafenib (GSK2118436) in patients with metastatic melanoma. J Clin Oncol. 2013; 31: 3205-3211.
13. Long GV, Trefzer U, Davies MA, et al., Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial. Lancet Oncol. 2012; 13: 1087-1095.
14. Sosman JA, Kim KB, Schuchter L, et al., Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med. 2012; 366: 707-714.
15. Kefford RF, Maio M, Arance A, et al., Vemurafenib in metastatic melanoma patients with brain metastases: an open-label, single-arm, phase 2, multicenter study [abstract]. Pigment Cell and Melanoma Res. 2013; 26: 965.
16. Larkin J, Del Vecchio M, Ascierto PA, et al., Vemurafenib in patients with BRAFV600 mutated metastatic melanoma: an open-label, multicentre, safety study. Lancet Oncol. 2014; 15: 436-444.
17. Flaherty KT, Infante JR, Daud A, et al., Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med. 2012; 367: 1694-1703.
18. Eisenhauer EA, Therasse P, Bogaerts J, et al., New Response Evaluation Criteria in Solid Tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009; 45: 228-247.
19. Carlino MS, Kwan V, Miller DK, et al., New RAS-mutant pancreatic adenocarcinoma with combined BRAF and MEK inhibition for metastatic melanoma. J Clin Oncol. 2015; 33: e52-e56.
20. Chan MM, Haydu LE, Menzies AM, et al., The nature and management of metastatic melanoma after progression on BRAF inhibitors: effects of extended BRAF inhibition. Cancer. 2014; 120: 3142-3153.
21. Ugurel S, Loquai C, Kahler K, et al., A multicenter DeCOG study on predictors of vemurafenib therapy outcome in melanoma: pretreatment impacts survival. Ann Oncol. 2015; 26: 573-582.
22. Flaherty K, Daud A, Weber JS, et al., Updated overall survival (OS) for BRF113220, a phase 1-2 study of dabrafenib (D) alone versus combined dabrafenib and trametinib (D+T) in pts with BRAF V600 mutation-positive (+) metastatic melanoma (MM) [abstract]. J Clin Oncol. 2014; 32 (suppl 5): 9010.
23. V600 mutation-positive metastatic melanoma (MM) who received vemurafenib (VEM): pooled data analyses from BRIM2 and BRIM3 [abstract]. Pigment Cell Melanoma Res. 2014; 27: 1179.
24. Schilling B, Sondermann W, Zhao F, et al., Differential influence of vemurafenib and dabrafenib on patients' lymphocytes despite similar clinical efficacy in melanoma. Ann Oncol. 2014; 25: 747-753.
25. Ho J, de Moura MB, Lin Y, et al., Importance of glycolysis and oxidative phosphorylation in advanced melanoma. Mol Cancer. 2012; 11: 76.
26. Lasithiotakis K, Leiter U, Meier F, et al., Age and gender are significant independent predictors of survival in primary cutaneous melanoma. Cancer. 2008; 112: 1795-1804.
27. de Vries E, Nijsten TE, Visser O, et al., Superior survival of females among 10,538 Dutch melanoma patients is independent of Breslow thickness, histologic type and tumor site. Ann Oncol. 2008; 19: 583-589.
28. Sondak VK, Swetter SM, Berwick MA,. Gender disparities in patients with melanoma: breaking the glass ceiling. J Clin Oncol. 2012; 30: 2177-2178.
29. Murali R, Brown PT, Kefford RF, et al., Number of primary melanomas is an independent predictor of survival in patients with metastatic melanoma. Cancer. 2012; 118: 4519-4529.
30. Eggermont AMM, Sileni VC, Grob J, et al., Efficacy, safety, and quality of life (QoL) data from the EORTC 18071 phase III trial of ipilimumab (Ipi) versus placebo after complete resection of stage III melanoma [abstract]. Ann Oncol. 2014; 25 (suppl 4): 10870.
31. Eggermont AM, Suciu S, Testori A, et al., Ulceration and stage are predictive of interferon efficacy in melanoma: results of the phase III adjuvant trials EORTC 18952 and EORTC 18991. Eur J Cancer. 2012; 48: 218-225.
32. McArthur GA, Chapman PB, Robert C, et al., Safety and efficacy of vemurafenib in BRAFV600E and BRAFV600K mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study. Lancet Oncol. 2014; 15: 323-332.
33. Menzies AM, Haydu LE, Visintin L, et al., Distinguishing clinicopathologic features of patients with V600E and V600K BRAF-mutant metastatic melanoma. Clin Cancer Res. 2012; 18: 3242-3249.
34. Mar VJ, Wong SQ, Li J, et al., BRAF/NRAS wild-type melanomas have a high mutation load correlating with histologic and molecular signatures of UV damage. Clin Cancer Res. 2013; 19: 4589-4598.
35. Wilmott JS, Long GV, Howle JR, et al., Selective BRAF inhibitors induce marked T-cell infiltration into human metastatic melanoma. Clin Cancer Res. 2012; 18: 1386-1394.
36. Frederick DT, Piris A, Cogdill AP, et al., BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma. Clin Cancer Res. 2013; 19: 1225-1231.
37. Kakavand H, Wilmott JS, Menzies AM, et al., PD-L1 expression and tumor-infiltrating lymphocytes define different subsets of MAPK inhibitor treated melanoma patients. Clin Cancer Res. epub 21st Jan 2015.